From Financial Modeling Prep: 2025-05-08 14:04:00

Knight Therapeutics Inc. (PNK:KHTRF) reported an EPS of $0.013, surpassing the estimated $0.003, but fell short on revenue with $61.1 million compared to the estimated $87.7 million. Revenues increased by 2% to $88 million in Q1 2025, driven by successful product launches. The gross margin was $34.9 million, representing 40% of revenues, down from 48% the previous year due to hyperinflation accounting in Argentina. Operating loss was $5.5 million, contrasting with an operating income of $2.7 million last year. Financial metrics show a high valuation with a P/E ratio of 139.21 and a price-to-sales ratio of 1.66. The company maintains a low debt-to-equity ratio of 0.062 and a current ratio of 3.57, indicating strong liquidity.



Read more at Financial Modeling Prep:: Knight Therapeutics Inc. (PNK:KHTRF) Earnings Repo…